Project Grant R01AI191221
- Federal Project Grant Award Summary Boston Medical Center Corporation received a $711,993 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) on June 11, 2025, with completion targeted for May 31, 2026. This award funds investigator-initiated biomedical research examining the effects of Mycobacterium tuberculosis (MTB) disease on HIV-1 (Human Immunodeficiency Virus) pathogenesis,...
- Federal Grant Award Summary Boston Medical Center Corporation received a $872,596 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective April 1, 2026 through March 31, 2031. The award supports investigative research examining HIV-1 antibody responses in people living with HIV who have concurrent tuberculosis (TB) and other opportunistic coinfections. The research will characterize...
- Federal Project Grant Summary Boston University Medical Campus received a $245,250 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective February 9, 2026, with completion by January 31, 2028. The award funds investigator-initiated biomedical research examining the mechanisms of alternative macrophage activation in pulmonary tuberculosis (TB), specifically investigating...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Boston Medical Center Corporation $795,622 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the MYTHIC (Mycobacterium Tuberculosis Impact on HIV Reservoir Clearance) project, effective May 1, 2026, through April 30, 2031. This investigator-initiated research project will deliver scientific knowledge and methodological advances addressing the intersection of...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Boston Children's Hospital $489,500 under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop innovative human cellular models for studying tuberculosis (TB) infection and innate immune responses. The award, effective August 1, 2025, through July 31, 2027, funds the establishment of a physiological in vitro lung alveolar epithelial cell organoid model derived...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Massachusetts General Hospital a $798,107 Project Grant on February 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct tissue-based research on tuberculosis-associated lung fibrosis and post-TB lung disease (PTLD). The research deliverables include the identification of molecular and cellular mechanisms driving fibrogenesis during tuberculosis...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Tufts University School of Medicine a $536,148 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective August 7, 2025, with a completion date of July 31, 2030. This research initiative integrates point-of-care urine isoniazid testing into routine tuberculosis (TB) care delivery in India to detect medication nonadherence and improve treatment...
- Federal Grant Award Summary Brigham & Women's Hospital Inc., through its Department of Faulkner Pathology, received a $484,752 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded September 23, 2025, with completion scheduled for August 31, 2027. The project investigates the use of chest radiography (CXR) to detect early-stage tuberculosis (TB) in children and youth within a...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Massachusetts Medical School a Project Grant totaling $832,076 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 8, 2025, with a completion date of July 31, 2030. This research initiative focuses on characterizing protective CD8 T cell responses to Mycobacterium tuberculosis (MTB) infection, with the ultimate objective of informing...
- Federal Project Grant Award Summary The University of Massachusetts Medical School received a $460,625 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective February 9, 2026, with a completion date of January 31, 2028. The award funds investigator-initiated biomedical research aimed at understanding vaccine-induced immunity to tuberculosis (TB), specifically examining how...
Grant Summary Boston Medical Center Corporation received a $487,764 Project Grant awarded on June 18, 2026, by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant funds the TACTIC (Tuberculosis Active Case Tracking via Interpersonal Connections) study, a five-year research initiative (through May 31, 2031) designed to evaluate innovative approaches for identifying tuberculosis (TB) cases among high-risk populations in Kampala, Uganda. The project will leverage respondent-driven sampling (RDS), a peer-based community recruitment strategy, to identify TB cases among people who use drugs (PWUD) and household contacts of individuals with active TB disease, with findings intended to be translatable to U.S. settings where TB outbreaks have been associated with methamphetamine, heroin, and crack cocaine use. The primary deliverables include comparative effectiveness research between the RDS-TB approach and traditional clinic-based index case household contact methods, screening of 2,000 PWUD and their household contacts, whole genome sequencing to characterize transmission dynamics, and evaluation of multiple diagnostic testing strategies including chest radiography with computer-aided detection, tongue swab testing for TB nucleic acid amplification tests, and sputum testing for TB nucleic acid amplification tests and mycobacterial culture. The research outcomes will identify the minimal diagnostic combination required for effective community-based active TB case finding and provide evidence-based recommendations for improving TB detection and treatment initiation in vulnerable populations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $487.8k | 6/19/26 |